
Alimera Sciences
Develops and commercializes prescription ophthalmic pharmaceuticals.
Market cap
$301m
Enterprise value
$360m
Share price
$5.54 ALIM
loading funding rounds…

Sofinnova(exited)

NEA(exited)

Palo Alto Investors(exited)

Domain Associates(exited)

Polaris Partners(exited)

Intersouth Partners(exited)

Scale Venture Partners(exited)

Venrock(exited)

Croft & Bender(exited)

Deerfield(exited)

OcuMension Therapeutics(exited)

Hercules Capital(exited)

Frank Torti(exited)
USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | 30 % | 16 % | (6 %) | 16 % | (8 %) | 49 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (38 %) | (19 %) | (5 %) | 4 % | 4 % | (17 %) | 8 % |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (61 %) | (35 %) | (19 %) | (11 %) | (7 %) | (33 %) | (25 %) |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | 36 % | 24 % | 20 % | 19 % | 23 % | 30 % | 21 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.